Rajeev Venkayya, MD

Rajeev Venkayya, MD is currently serving as the Chief Executive Officer of Aerium Therapeutics, a company developing monoclonal antibodies and antivirals for SARS-CoV-2 and future epidemic and pandemic threats. Rajeev is also an independent member of the board of CEPI and a member of the board of the International AIDS Vaccine Initiative. Prior to their current role, Rajeev was the President of Takeda Pharmaceuticals' Global Vaccine Business Unit and oversaw the company's contract with the U.S. government. Rajeev also held various roles at the Bill & Melinda Gates Foundation, including Director of Vaccine Delivery, where they focused on polio eradication and new vaccine introduction. Rajeev has also served in positions at The White House, including Special Assistant to the President for Biodefense and as a White House Fellow. Prior to their work in public health, they were an Assistant Professor of Medicine at the University of California, San Francisco, specializing in Pulmonary and Critical Care Medicine.

Rajeev Venkayya, MD completed their medical education at Northeast Ohio Medical University (NEOMED), earning a degree in Medicine (M.D.). Following their medical degree, they pursued a residency in Internal Medicine at the University of Michigan. After completing their residency, they continued their training at the same institution, becoming a Chief Medical Resident in Internal Medicine. Rajeev further specialized in the field of Pulmonary and Critical Care Medicine through a Fellowship at the University of California, San Francisco.